These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 17308048)
1. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Goldsmith ME; Aguila A; Steadman K; Martinez A; Steinberg SM; Alley MC; Waud WR; Bates SE; Fojo T Mol Cancer Ther; 2007 Feb; 6(2):496-505. PubMed ID: 17308048 [TBL] [Abstract][Full Text] [Related]
2. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Goldsmith ME; Kitazono M; Fok P; Aikou T; Bates S; Fojo T Clin Cancer Res; 2003 Nov; 9(14):5394-401. PubMed ID: 14614025 [TBL] [Abstract][Full Text] [Related]
3. Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression. Taura K; Yamamoto Y; Nakajima A; Hata K; Uchinami H; Yonezawa K; Hatano E; Nishino N; Yamaoka Y J Gene Med; 2004 May; 6(5):526-36. PubMed ID: 15133763 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494 [TBL] [Abstract][Full Text] [Related]
5. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. Okegawa T; Nutahara K; Pong RC; Higashihara E; Hsieh JT J Urol; 2005 Aug; 174(2):747-52. PubMed ID: 16006969 [TBL] [Abstract][Full Text] [Related]
6. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. Okegawa T; Sayne JR; Nutahara K; Pong RC; Saboorian H; Kabbani W; Higashihara E; Hsieh JT J Urol; 2007 Mar; 177(3):1148-56. PubMed ID: 17296436 [TBL] [Abstract][Full Text] [Related]
7. Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems. Kobayashi M; Okada T; Murakami T; Ozawa K; Kobayashi E; Morita T Urology; 2007 Dec; 70(6):1230-6. PubMed ID: 18158067 [TBL] [Abstract][Full Text] [Related]
8. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Kitazono M; Goldsmith ME; Aikou T; Bates S; Fojo T Cancer Res; 2001 Sep; 61(17):6328-30. PubMed ID: 11522619 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models. Sasaki Y; Negishi H; Idogawa M; Suzuki H; Mita H; Toyota M; Shinomura Y; Imai K; Tokino T Mol Cancer Ther; 2008 Apr; 7(4):779-87. PubMed ID: 18413792 [TBL] [Abstract][Full Text] [Related]
10. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611 [TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Sasakawa Y; Naoe Y; Noto T; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S Biochem Pharmacol; 2003 Sep; 66(6):897-906. PubMed ID: 12963476 [TBL] [Abstract][Full Text] [Related]
12. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Robey RW; Zhan Z; Piekarz RL; Kayastha GL; Fojo T; Bates SE Clin Cancer Res; 2006 Mar; 12(5):1547-55. PubMed ID: 16533780 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420 [TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication. Danielsson A; Dzojic H; Rashkova V; Cheng WS; Essand M PLoS One; 2011 Feb; 6(2):e14700. PubMed ID: 21379379 [TBL] [Abstract][Full Text] [Related]
16. Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application. Pong RC; Roark R; Ou JY; Fan J; Stanfield J; Frenkel E; Sagalowsky A; Hsieh JT Cancer Res; 2006 Sep; 66(17):8822-8. PubMed ID: 16951199 [TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804 [TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway. Li LH; Zhang PR; Cai PY; Li ZC Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351 [TBL] [Abstract][Full Text] [Related]
19. [Inhibitory effect of a novel histone deacetylases inhibitor FK228 on human colon cancer HCT-116 cells in vitro and in vivo]. Xu DB; Wang YL; Yue Y; Wu SC; Ding H Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):814-8. PubMed ID: 24447477 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]